In this section

Filter by year:
Back

News & events

Loading loading...

  • NIH extends agreement with BioFocus DPI


    Tue 22 Jul 2008
    The U.S. National Institutes of Health (NIH) have extended their agreement with Galapagos’ service division BioFocus DPI for the operation of the Molecular Libraries Small Molecule Repository (MLSMR) until December 2010. According to the terms of this agreement, BioFocus DPI will receive more than $9 million (€5.7 million) over the course of the two year extension.

  • Boehringer Ingelheim licenses drug targets from autoimmune collaboration with BioFocus DPI


    Thu 17 Jul 2008
    BioFocus DPI announced today that Boehringer Ingelheim has exercised its right to license two drug targets from its autoimmune research agreement, resulting in a milestone payment to BioFocus DPI.

  • BioFocus DPI signs new compound management agreement


    Mon 30 Jun 2008
    BioFocus DPI will provide compound management and related services to Sepracor Inc., a leader in respiratory and central nervous system disorder medicines. Under the terms of the agreement, BioFocus DPI will receive, register, and store selected compounds from Sepracor’s proprietary compound library, and plate and replicate these compounds for a period of three years.

  • California stem Cell and BioFocus DPI to collaborate in ALS Association-funded research using human motor neurons


    MOTORPLATE™ 96 Assay-Ready Well Plates Enable High Throughput and High Content Screening Assays
    Tue 20 May 2008
    California Stem Cell, Inc. (CSC) will supply international drug discovery organization BioFocus DPI, the service division of Galapagos, with its MOTORPLATE™ 96 assay-ready well plates, containing motor neuron progenitors (MNPs) derived from human embryonic stem cells (hESC).

  • BioFocus DPI to perform medicinal chemistry services for UCL research project


    Mon 19 May 2008
    Galapagos NV (Euronext: GLPG) announced today that is has signed a drug discovery research agreement with UCL (University College London). Galapagos’ BioFocus DPI service division will perform medicinal chemistry services for a UCL research project. It is also intended that BioFocus DPI will offer UCL ADME screening facilities during the appropriate stages of the work.

  • Galapagos and Allergan enter drug discovery collaboration


    Tue 06 May 2008
    Mechelen, Belgium; 6 May 2008 – Galapagos NV (Euronext: GLPG) announced today that Galapagos’ service division, BioFocus DPI, will provide hit-finding services for multiple Allergan, Inc. targets. Total contract value for Galapagos could reach up to €1.3 million over the next 12 months, contingent on the number of BioFocus DPI compounds screened.

  • BioFocus DPI releases five new compound libraries


    Tue 08 Apr 2008
    BioFocus DPI today introduces new FieldFocus and SoftFocus libraries that were created with advanced modeling tools. The libraries consist of novel drug-like compounds specifically targeted towards kinases and voltage-dependent ion channels. These targets represent two of the most important and commonly studied protein classes for drug discovery.

  • BioFocus DPI launches ‘Intelligent Screening’ platform at SBS


    New approach to accelerating drug discovery programs
    Mon 07 Apr 2008
    BioFocus DPI is launching a new approach to discovery biology at the Society for Biomolecular Sciences Annual Conference taking place in St. Louis. Called ‘Intelligent Screening’, this approach focuses on combining the know-how and expertise of BioFocus DPI’s scientists with extensive high-throughput and information-rich screening capabilities to generate faster results and accelerate partners’ drug discovery programs.

  • BioFocus DPI takes global license for Cresset’s molecular field software


    Wed 19 Mar 2008
    BioFocus DPI and Cresset BioMolecular Discovery announced today that BioFocus DPI has up-graded its software license with Cresset to provide global access to the entire range of Cresset’s molecular field software for use in drug discovery.

  • BioFocus DPI to distribute NIH’s Clinical Compound Collection


    Tue 18 Mar 2008
    BioFocus DPI, a Galapagos Company, announces the launch of the U.S. National Institutes of Health Clinical Compound Collection (NCC). The collection currently contains 446 bioactive compounds, most of which are known drugs. The NCC is managed and distributed through BioFocus DPI’s Compound Management facility, home to the NIH’s Molecular Libraries Small Molecule Repository.



Bookmark with:

What are these?


Print to HTML Print as PDF Send to a friend


Related links


Get in contact with us









Where to find usSubscribe to the RSS feed

view all events

 


BioFocus®, SoftFocus®, Galapagos®, SilenceSelect® and FLeXSelect® ThemePair™, FieldFocus™, HDRA™. Helical Domain Recognition Analysis™, 2D Roadmap™, Thematic Analysis™, SFK™, SFI™, SFG™ and PrimePath™ are trademarks of Galapagos NV and/or its affiliates.